SHH · 603259.SS
WuXi AppTec Co., Ltd.
CN¥142.89+CN¥0.49 (+0.34%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 17.69% below the high.
Loading market information…
NASDAQ · ICLR · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
ICON Public Limited Company’s quoted price sits in the upper half of its reported 52-week range, 1.61% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
ICON Public Limited Company’s next earnings report is currently expected on Feb 24, 2027, with estimated earnings per share of $2.84. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow ICON Public Limited Company’s reporting calendar.
THE COMPANY BEHIND THE TICKER
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:39 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2025 | Jul 23, 2025 | $3.26+2.19% vs estimate | $2.02B+1.8% vs estimate |
|---|
| Q1 2025 | Apr 30, 2025 | $3.19+2.57% vs estimate | $2.00B-0.32% vs estimate |
|---|
| Q4 2024 | Feb 19, 2025 | $3.43+0.59% vs estimate | $2.04B+0.24% vs estimate |
|---|
THE ANALYST VIEW
30 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 13 contributors · Median target $235.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥142.89+CN¥0.49 (+0.34%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 17.69% below the high.
$275.06-$3.98 (-1.43%)
IQVIA Holdings Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.32% below the high.
$368.16+$7.91 (+2.2%)
Labcorp Holdings Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.77% below the high.
$677.56-$15.12 (-2.18%)
Medpace Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.36% below the high.
$376.10+$2.12 (+0.57%)
Charles River Laboratories International, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.93% below the high.
CN¥40.00+CN¥0.40 (+1.01%)
Pharmaron Beijing Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 25.33% below the high.
CN¥48.19-CN¥0.07 (-0.15%)
Hangzhou Tigermed Consulting Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 28.98% below the high.
CN¥45.78-CN¥1.07 (-2.28%)
Joinn Laboratories(China)Co.,Ltd.’s quoted price sits in the upper half of its reported 52-week range, 17.78% below the high.
